As medical director and co-founder, I strive to create a care experience that focuses on the person not just the disease. With this in mind, our center brings together experts in care and healing, respects the needs and interest of the person and empowers both patient and clinician to find new ways to treat a problem. The focus is not just on the services provided but begins with a shared philosophy of caring that is rooted in the expertise and strengths of each member of our team- including you the patient.
Philosophy of Care:
True healing requires more than treatment of disease; true healing embraces mind, body, and soul to support wholeness even when disease changes a person’s health. I believe the first step is to partner with the patient, understand their unique needs, values and goals when it comes to health and wellness. An empowered patient will feel and perform better with any disease. Below is an interview where I talk about a patient centered care project I completed with co-author Sierra Farris in 2009 that emphasizes my commitment to my patients living their best every day with Parkinson’s disease. The book, called Every Victory Counts is published and available from the Davis Phinney Foundation.
Clinical Fellow, Integrative Medicine, University of AZ; 2009-2011
Clinical Fellow, Movement Disorders, Functional Neuroimaging of Movement Disorders, Emory University, Dept. of Neurology, and Div. of Nuclear Medicine, Atlanta. GA; 1996-1998
Administrative Chief Resident and Instructor in Neurology, Yale New Haven Hospital, CT; 7/93 – 6/96
Internal Medicine Internship, Yale New Haven Hospital, New Haven, CT; 7/92 – 6/93
Medical Degree, Ohio State Univ. College of Medicine, Columbus, OH; 1992
Clinical Interest and Expertise:
Neurology, movement disorders, holistic health, Integrative medicine, wellness coaching, mindfulness therapy. Training in Therapeutic yoga, mindfulness based therapy and stress reduction and integrative medicine.
2010 Program Director, National Care Center Consortium, National Parkinson’s Foundation, Miami.
2005 Medical Faculty, National Parkinson’s Foundation, Interdisciplinary Team Training Program.
2009 Medical Director, Northwest Parkinson’s Foundation, Director Wellness Center, www.nwpf.org/wellness, Seattle.
2007 Northwest Parkinson’s Foundation, Board Member, Seattle WA
Awards and Honors:
2007 Paragon Award for exemplary teamwork in medicine, American Academy of Physician Assistants.
2006 Cleveland Clinic Shining Star Award for outstanding PA-MD team of the year.
Online Patient and Professional Education
Every Victory Counts: An Essential Guide for Living Well with Parkinson’s disease. 2010 Author: Monique Giroux, MD and Sierra Farris, PA-C.www.everyvictorycounts.org.
Medical Director and Webmaster, Northwest Parkinson’s Foundation Virtual Wellness Center, www.nwpf.org/wellness.
Comprehensive Care in Parkinson’s disease. Book Chapter in Movement Disorders , Ron Pfieffer, MD. 2012.
Giroux, ML, Parkinson’s disease: Treating the whole patient. Cleveland Clinic Journal 2007: 74: 313-328.
Kubu, CS, Giroux, ML, Rezai, AR. Depression and memory changes following DBS in Patients with Parkinson Disease. International Neuropsychological Society, Feb. 2007.
Pandya M, Kubu C, Giroux ML. The many faces of Parkinson’s disease: not just a movement disorder. Cleveland Clinic Journal 2008:75; 856-865
Farris S, Giroux ML, Vitek J. Safety and efficacy of rivastigmine in Parkinson’s disease patients with dementia, a retrospective review. Movement Disorders 2004, S274.
Lee JYK, Machado A, Deogaonkur M, Kubu C, Farris S, Giroux M, Vitek J, Rezai A: Thalamic Deep Brain Stimulation for Tourette’s Syndrome. International Society of Reconstructive Neurosurgery, Seoul, South Korea, September 1-3, 2005.
Farris S , Giroux, ML. Gait changes after Deep Brain Stimulation for Parkinson’s Disease in a patient with cervical myelopathy. Neurorehabilitation 2007: 24:84-90.
Rueda-Acevedo, M; Farris, S; Senatus, P; Giroux, ML. Controlling dyskinesias in Parkinson’s disease patients with STN DBS. A new programming strategy. American Academy of Neurology 2007.
Farris S, Giroux ML. Self-reported change in review of systems post bilateral subthalamic deep brain stimulation. Movement Disorders Conference, Chicago, 2008
Farris S, Zylstra A, Giroux ML: Change in exertional O2 saturation with deep brain stimulation in Parkinson’s disease. Movement Disorders Conference, Chicago, 2008
Giroux, ML, Farris, S. An Analysis of Hope and Wellness in various stages of Parkinson’s disease, World Parkinson’s Congress, 2008
Farris S, Giroux ML . Every Victory Counts: A patient centered self-management guide to enhance Parkinson’s QOL, World Parkinson’s Congress, 2008
Giroux ML, Farris, S. Treating Parkinson’s disease: The impact of different care models on quality of life. Topics in Geriatric Rehabilitation 2008: 24:83-89.
Farris, S, Giroux ML. Deep brain stimulation hardware complications: The Role of Electrode Impedance Measurements. Movement Disorders 2008: 23: 755-759.
Farris S, Ford P, Giroux ML. Deep Brain Stimulation and the Ethics of Protection and Caring for the Patient with Parkinson’s Dementia. Movement disorders.2008; Online ahead of print August.
Giroux, ML and Farris, SM. Patient Centered Care: Taking an Active Role. Parkinson’s Report Official Journal of the National Parkinson’s Foundation. 2009, 20,1, 2-4.
Giroux, ML and Farris SM. Basic aspects of deep brain stimulation programming in Parkinson’s disease. Editor: Mauricio Rueda Acevedo, MD and Luz Jaqueline Ruiz, MD. Assoc Colombiana de Neurologia, Chapter 27 Parkinson’s Disease: Update and Review, ISBN: 978-958-99088-2-2;2009.
Giroux, ML and Farris, SM. Lead Wire Fracture associated with Normal Electrode Impedance Measurements in a Patient with a Kinetra neurostimulator. Neuromodulation 2010, 13: 65-67
Farris S, Giroux ML. Deep brain stimulation review for the community based practitioner, perspectives from 10 years’ experience. Journal of the American Academy of Physician Assistants, Accepted January 2010
Deep Brain Stimulation: Guidelines for the Community Neurologist. Submitted Neurology, 2012
An analysis of healthcare delivery in Parkinson’s disease; in progress, National Parkinson’s Foundation, Principle Investigator 2012
An analysis of Hope and Wellness throughout the stages of Parkinson’s disease 2010-2011; Principle Investigator
Deep Brain Stimulation Troubleshooting Outcomes Project 2011-2012; Principle Investigator
Target Location of DBS (TARGET): A Retrospective Observational Study 2010 to 2010; Principle Investigator: Intelect Medical
TEVA PM 102 Investigation of the Occurrence of Serotonin Toxicity in PD patients treated concomitantly with Rasagiline and Antidepressants, Retrospective Review 2010 to 2010; Principle Investigator
Graphical User Interface for DBS Evaluation Software Study (GUIDE), 12 Month Software Evaluation 2009 to 2010; A Software Evaluation Study Version 1.0. Intellect, Inc. Evaluate the effectiveness of a computerized software system incorporating a mathematical model of stimulation efficacy for patients with Parkinson’s disease and Deep Brain Stimulation (Co-investigator) Intelect Medical
Using the Chronic Care Model to evaluate Comprehensive Care for Parkinson’s disease (Principle Investigator), National Parkinson’s Foundation, 2008-09
Outreach Project- Focus on Wellness, National Parkinson’s Foundation, National Parkinson’s Foundation, 2008-09
Open-Label, 6-12 Month Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa Responsive Subjects with Advanced Parkinson’s Disease 2008 to 2010; Principle Investigator: Solvay Pharmaceuticals Protocol S187.3.004,
Multi-center, double blind, randomized, placebo controlled, parallel group, induction study to assess the clinical effect of droxidopa in subjects with primary autonomic failure 2009 to 2010; Principle Investigator: Chelsea Therapeutics Protocol 301,
Using fMRI to Predict Therapeutic Response to DBS in Patients with Parkinson’s disease 2006 to 2007; Co-Investigator: Cleveland Clinic,
CERE-120; Randomized, Double-Blind, Sham Surgery-Controlled Study of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) to Assess the Efficacy and Safety of Bilateral Intraputaminal (IPu) Delivery in Subjects with Idiopathic Parkinson’s Disease. 2006 to 2007; Principle Investigator: Ceregene, Cleveland clinic,
A randomized, double-blind, placebo controlled, parallel-group clinical trial to examine the efficacy and safety of early Pramipexole treatment versus delayed Pramipexole treatment in patients with new onset Parkinson’s disease, 2006 to 2007; Principle Investigator: Boehinger Ingelheim,